RESEARCH 研究の報告

2024.9.1

A retrospective evaluation of therapeutic efficacy and safety of chemoradiotherapy in older patients (aged ≥ 75 years) with limited-disease small cell lung cancer: insights from two institutions and review of the literature.

著者 Shiono A, Imai H, Endo S, Katayama K, Sato H, Hashimoto K, Miura Y, Okazaki S, Abe T, Mouri A, Kaira K, Masubuchi K, Kobayashi K, Minato K, Kato S, Kagamu H.

Radiol Oncol. 2024 Sep 15;58(3):432-443. doi: 10.2478/raon-2024-0054. eCollection 2024 Sep 1.

PMID: 39287161 Free PMC article. Review.

2024.8.5

The Glasgow Prognostic Score as a Predictor of Survival after Chemoradiotherapy for Limited-Disease Small Cell Lung Cancer.

著者 Endo S, Imai H, Shiono A, Hashimoto K, Miura Y, Okazaki S, Abe T, Mouri A, Kaira K, Masubuchi K, Masubuchi T, Kobayashi K, Minato K, Kato S, Kagamu H.

Oncology. 2024 Aug 5:1-11. doi: 10.1159/000540651. Online ahead of print.

PMID: 39102792

2024.7.3

Therapeutic Resistance in G-CSF Producing Lung Cancer With EGFR Mutation.

著者 Ito K, Kaira K, Imai H, Shiono A, Hashimoto K, Yamaguchi OU, Kagamu H.

Cancer Diagn Progn. 2024 Jul 3;4(4):529-533. doi: 10.21873/cdp.10359. eCollection 2024 Jul-Aug.

PMID: 38962554 Free PMC article.

2024.5.20

Prior immune checkpoint inhibitors may enhance severe hypersensitivity related to selpercatinib in RET fusion gene-positive lung cancer.

著者 Hashimoto K, Kaira K, Imai H, Shiono A, Kagamu H.

J Chemother. 2024 May 20:1-3. doi: 10.1080/1120009X.2024.2352985. Online ahead of print.

PMID: 38766697